Lyxumia could expedite moving patients to final drug dose

09/12/2011 | Bloomberg

A study of 482 patients with diabetes who used Sanofi's experimental Lyxumia found the drug improved blood-glucose levels when the dosage was doubled after two weeks or increased over three weeks, experts reported at the European Association for the Study of Diabetes conference. The drug, which also helped patients lose weight, could help doctors more quickly advance patients to the ideal drug dosing.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA